Gilead Sciences, Inc.
GILDNASDAQHealthcare● Active
$129.16
$-0.02(-0.02%)
Market Cap$160.4B
P/E Ratio—
52W High$157.29
52W Low$104.46
Gilead Sciences, Inc. (GILD) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GILD · as of 2026-06-08
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $8.51B | $0.48B | $5.67B | $4.59B | $6.20B |
| Depreciation & Amort. | $2.76B | $2.77B | $2.69B | $2.10B | $2.05B |
| Stock-Based Comp. | $0.00B | $0.83B | $0.77B | $0.64B | $0.64B |
| Change in Working Capital | ($3.95B) | ($0.88B) | ($2.30B) | ($1.76B) | $0.49B |
| Net Cash from Operations | $10.02B | $10.83B | $8.01B | $9.07B | $11.38B |
| Investing Activities | |||||
| Capital Expenditure | ($0.56B) | ($0.52B) | ($0.58B) | ($0.73B) | ($0.58B) |
| Purchases of Investments | ($4.07B) | ($0.74B) | ($2.37B) | ($1.94B) | ($3.90B) |
| Sales of Investments | $0.91B | $2.59B | $1.84B | $2.00B | $2.91B |
| Net Cash from Investing | ($4.79B) | ($3.45B) | ($2.27B) | ($2.47B) | ($3.13B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($1.92B) | ($1.15B) | ($1.00B) | ($1.40B) | ($0.55B) |
| Dividends Paid | ($4.00B) | ($3.92B) | ($3.81B) | ($3.71B) | ($3.60B) |
| Debt Issued / Repaid | ($1.79B) | $1.49B | ($0.27B) | ($1.50B) | ($4.75B) |
| Net Cash from Financing | ($7.75B) | ($3.43B) | ($5.13B) | ($6.47B) | ($8.88B) |
| Free Cash Flow | |||||
| Free Cash Flow | $9.46B | $10.30B | $7.42B | $8.34B | $10.80B |
| FCF Margin %(computed) | 32.12% | 35.84% | 27.37% | 30.59% | 39.57% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Gilead Sciences, Inc. data
About Gilead Sciences, Inc. (GILD) Cash Flow Statement
Gilead Sciences, Inc. generated operating cash flow of $10.02B and free cash flow of $9.46B for 2025 — a FCF margin of 32.12%. Capital expenditure was ($0.56B).
Frequently asked questions
GILD · 4 questionsGilead Sciences, Inc. generated free cash flow of $9.46B for 2025, down 8.2% year-over-year.
GILD free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08